BioCryst Pharmaceuticals Inc

BioCryst's 8.33 P/E is remarkably compressed for a biotech firm, suggesting either deep undervaluation or unpriced risk. The stock trades 15.28% short—a meaningful position that could amplify moves if sentiment shifts—yet RSI at 45.7 shows no extreme momentum either direction, sitting in neutral territory. The company isn't at 52-week highs despite the low valuation multiple, implying recent weakness or market skepticism about pipeline prospects. This setup hints at a classic value trap or a genuine mispricing, depending on whether BCRX's earnings justify the discount to sector peers, but the short float combined with depressed valuation creates latent squeeze potential if clinical catalysts or institutional rotation reignites demand.